Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Principaux documents

Voir toute la documentation

SML2741

Sigma-Aldrich

Sultopride hydrochloride

≥98% (HPLC)

Synonyme(s) :

(±)-Sultopride HCl, LIN 1418 HCl, LIN1418 HCl, N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide hydrochloride, N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-o-anisamide monohydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C17H26N2O4S·HCl
Numéro CAS:
23694-17-9
Poids moléculaire :
390.93
Numéro MDL:
MFCD01319147
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Essai

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated

Couleur

white to beige

Solubilité

H2O: 2 mg/mL, clear

Température de stockage

−20°C

Chaîne SMILES 

[S](=O)(=O)(CC)c1cc(c(cc1)OC)C(=O)NCC2[N+H](CCC2)CC.[Cl-]

InChI

1S/C17H26N2O4S.ClH/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3;/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20);1H

Clé InChI

IGOWMQPOGQYFFM-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Orally active benzamide class dopamine receptor D2/3-selective antagonist (Ki = 18 nM/D2, 22 nM/D3, 7.7 μM/D4, >10 μM/D1) with in vivo antipsychotic efficacy.
Sultopride is an orally active benzamide class dopamine receptor D2/3-selective antagonist (Ki = 18 nM/rat D2, 22 nM/human D3, 7.7 μM/human D4, >10 μM/rat D1 by competitive binding against 0.5 nM Spiperone, 0.2 nM YM-09151-2, 5 nM Spiperone, 0.2 nM SCH23390 for respective receptor) that displays in vivo antipsychotic efficacy with moderate atypical index. Sultopride exhibits little or no affinity toward 5-HT1A2/33, adrenaline receptor α1/α2, Ach receptor, histamine receptor H1, or Sigma receptors σ1/σ2. Sultopride is a racemic material composed of the highly active (-) and the less potent (+) enenatiomers.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Conseils de prudence

P301 + P312 + P330

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Takuro Oka et al.
Life sciences, 76(2), 225-237 (2004-11-03)
Acute administration of typical and atypical antipsychotics has been reported to induce regionally distinct patterns of c-Fos expression in the rat forebrain. Furthermore, atypical index, the difference in the extent of increased Fos-like immunoreactivity (Fos-LI) in the nucleus accumbens (NAc)
Jun-ichi Karasawa et al.
Pharmacology, biochemistry, and behavior, 73(3), 505-510 (2002-08-02)
(R)-(+)-1-(4-Chlorophenyl)-3-[4-(2-methoxyethyl)piperazin-1-yl]methyl-2-pyrrolidinone L-tartrate (MS-377) is a novel antipsychotic agent with selective and high affinity for sigma(1) receptor. The present study was carried out to clarify the interaction of MS-377 with dopamine D(2) receptor antagonists (D(2) antagonists) in concurrent administration, and then
Akihiro Takano et al.
The international journal of neuropsychopharmacology, 9(5), 539-545 (2005-11-18)
Conventional antipsychotics tend to elicit extrapyramidal symptoms at clinical doses, but dose optimization could reduce the risk of such side-effects. In-vivo receptor-binding studies have suggested that 70-80% of dopamine D2 receptor occupancy provides the desired antipsychotic effects without extrapyramidal symptoms.
Profiles of the Affinity of Antipsychotic Drugs for Neurotransmitters and Their Clinical Implications
Yonemura K, Miyanaga K, Machiyama Y
Kitakanto Medical Journal, 48(2), 87-102 (1998)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique